insurers glp-1 coverage news Costly Drugs are Rarely Covered for Weight Loss by Marketplace Plans Some insurers are dropping GLP-1
Description
The use of GLP-1RA is a new therapeutic strategy that addresses both metabolic and cognitive/neuropsychiatric aspects, which is fundamentally important for the treatment of comorbid diseases.
Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D)
Glucagon-like peptide receptor agonists (GLP-1 RAs) now available to promote weight lossWegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)could potentially make much needed gains against the obesity epidemic
90-day protocol supports against gut-bacterial burnout to maintain results after healthy-weight loss shots
75g protein per 100g hit your protein target even when appetite is low
Directions for Use & Ingredients
